Ascendis Pharma (ASND) Stock Forecast & Price Target

Ascendis Pharma is compelling because its TransCon platform now supports three commercial growth engines, with YORVIPATH driving current revenue, SKYTROFA providing a stable base, and YUVIWEL adding a differentiated weekly achondroplasia option that improves convenience versus daily injections. YUVIWEL’s early U.S. launch has surpassed 220 unique patient enrollments across more than 100 prescribers with over 65% reimbursement approval, while YORVIPATH revenue reached €252 million in 2Q26 and the company reported €812 million in cash and cash equivalents as of June 30, 2026. Beyond commercialization, durable 78-week COACH data, planned Phase 3 starts in 2H26 and 4Q26, and expected operating leverage from a lean cost base support a credible path to sustained revenue and cash-flow growth.

Ascendis Pharma is a commercial and clinical-stage biotechnology company exposed to meaningful execution risk across clinical readouts, regulatory uncertainty, manufacturing, competition, and litigation, all of which can impair confidence in its TransCon platform. Although 2Q26 showed commercial momentum with YORVIPATH up ~26% Q/Q, SKYTROFA up ~24%, and YUVIWEL contributing its first ~$8.8M, the business still faces heavy reliance on U.S. uptake, reimbursement, and durable patient persistence. Its negative outlook is reinforced by the upcoming ITC decision, the Dec. 21 Commission decision, and the risk that adverse confirmatory data, label restrictions, pricing pressure, or patent-related import limits could curb growth and operating leverage.